Today at #AACR25, Brooke Felsheim and Charles Perou, PhD, will be provide updates from #SABCS24
⌚️: 10:15 a.m. - 11:45 a.m. CT
📍: Room S103
3
2
0
0
Hashtag
#SABCS24
Advertisement · 728 × 90
This year’s San Antonio Breast Cancer Symposium featured several notable developments from ongoing breast cancer clinical trials—including many that BCRF supports or that involve BCRF investigators. @sabcs.bsky.social #SABCS24
Find the full recap here: bit.ly/3Xd6tv7
3
0
0
0
OSU SABCS meeting - 200 participants in attendance. Great turn out and awesome presentations by our amazing Breast Cancer team. Very proud of them 🙂👏
@OhioStateMedOnc
@StoverLab @quirogad @CherianMathew30 Maggie Gatti-Myes and all team!
#SABCS24
@OSUCCC_James @OhioStateMed
2
1
0
0
Last but not least, Dr. Sharifi presenting on Genomics/Precision Medicine #SABCS24 abstracts. @uwhealth.bsky.social
0
0
0
0
What a great day of #SABCS24 @sabcs.bsky.social updates in Wisconsin co-hosted by UWCarbone, MCW and WI Association of Heme/Onc.
1
0
0
0
Dr. Bethany Anderson eloquently presents #SABCS24 radiation abstracts at the WI Best of SABCS. Key theme is individualization based on cancer features and pt preferences. @uwhealth.bsky.social
1
0
0
0
SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors
@sabcs.bsky.social #SABCS24 #bcsm #oncology
www.onclive.com/view/shr-a18...
0
0
0
0
Join our collaborators at OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer straight out of
#SABCS24
Link to view: buff.ly/3CpGyc8
with Dr. @elisaagostinetto.bsky.social from Jules Bordet Institut
3
0
0
0
Register: Yale’s Post-San Antonio Breast Cancer Symposium #SABCS24 #CME webinars:
🔹Jan. 30, 6pm: Advances in #breastcancer care
🔹Feb. 6, 6pm: Advances in systemic therapy options for early-stage breast cancer
🔹Feb. 13, 6pm: New treatments for #mbc
RSVP➡️ bit.ly/40ffiVM
@maryamlustberg.bsky.social
8
3
0
0
🎥@avantikagupta.bsky.social of @mskcancercenter.bsky.social discusses APOBEC3 signatures as biomarkers of poor outcomes in mBC. Targeting APOBEC-PIK3CA mutations may boost PI3K-alpha inhibitor sensitivity:
➡️https://buff.ly/42i4cC1⬅️
@sabcs.bsky.social #SABCS24 #BCSM #breastcancer
7
1
0
0
SABCS Update Session Graphic
Join us 1/24 11 a.m. – Noon for a 2024 San Antonio Breast Cancer Symposium Update on MBC with Hal Burstein, MD, PhD, part of the EMBRACE Metastatic Breast Cancer Virtual Forum Series. A Q&A will follow the talk.
https://bit.ly/4e1UUfu
#MBC #breastcancer #metastaticbreastcancer #SABCS24
3
1
0
0
🎥 @guinadermarta.bsky.social of @danafarber.bsky.social discusses PACE trial (NCT03147287) insights on TKa dynamics as prognostic biomarkers and ctDNA-based DNADX tumor subtypes in ER+/HER2- breast cancer:
➡️ https://buff.ly/4gPb4LD ⬅️
@sabcs.bsky.social #SABCS24 #BreastCancer #BCSM
3
2
0
0
Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer
@sabcs.bsky.social #SABCS24
www.onclive.com/view/zanidat...
1
0
0
0
Congrats to all #BigTen cancer researchers who presented at #SABCS24. Our team managed to visit some of your posters, but there were so many others at the meeting. Wish we could have visited all! @osucccjames.bsky.social @rutgerscancer.bsky.social
1
0
0
0
1
0
0
0
Congratulations to @rutgerscancer.bsky.social and @georgemasonu.bsky.social collaborators on your #SABCS24 poster, validation of HER2 activation response predictive signature (HARPS) as predictive biomarker for HER2+ therapy response in neoadj setting.
3
1
0
0
🎥@drgattimays.bsky.social discusses a Phase Ib/II trial (NCT06026657) combining TGFβi NK cells, gemcitabine, and naxitamab for metastatic HER2-/GD2+ breast cancer:
➡️ https://buff.ly/41XWj4J ⬅️
@sabcs.bsky.social #SABCS24 #BreastCancer #Immunotherapy
3
0
0
0
We are grateful to all who joined the HCRN #breastcancer research meeting at #SABCS24. Great discussion on currently enrolling studies and potential new multi-center IITs.
0
0
0
0
UNC Lineberger's Jean Wright, MD, FASTRO, presented pivotal findings at #SABCS24, revealing that adjuvant tamoxifen significantly reduces the 15-year risk of recurrence in patients with 'good-risk' DCIS who forgo radiation therapy. ascopost.com/news/january...
2
0
0
0
13/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
6
4
3
0
Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer @yalecancer.bsky.social @yalemed.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #oncology
www.onclive.com/view/emergin...
2
0
0
0
#TumorBoardTuesday
We have not heard any updates from #SABCS24 yet!
📢So join us Tuesday, 01-14-25 at 8PM ET here & on Twitter as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer
RT and bring others into the discussion‼️
9
5
1
0
SABCS24 Highlights with Laura Huppert – Oncology Brothers
oncodaily.com/blog/sabcs24...
@sabcs.bsky.social
@laurahuppert.bsky.social
@oncbrothers.bsky.social
#Cancer #OncoDaily #Oncology #OncologyBrothers #SABCS24 #Medicine #Health
10
0
0
0
Continuing our coverage of the news from #SABCS24, this video with Nan Chen, MD, discusses the impact of anthracyclines in high genomic risk node-negative HR-positive/HER2-negative #breastcancer.
ascopost.com/videos/2024-...
4
0
0
0
Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer @elmayermd.bsky.social @danafarber.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #oncology www.onclive.com/view/neoadju...
1
0
0
0
Learn about final survival results from the WSG ADAPT-HR+/HER2-negative chemotherapy trial in this video from #SABCS24 featuring Sherko Kuemmel, MD.
ascopost.com/videos/2024-...
#breastcancer
4
0
0
0
In this video @breastcancerdoc.bsky.social discusses the results of the phase III EMBER-3 trial of imlunestrant. She presented on this oral selective estrogen receptor degrader for #breastcancer treatment at #SABCS24.
ascopost.com/videos/2024-...
9
4
0
0
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer #SABCS24
https://buff.ly/4iSMoU6
@elisaagostinetto.bsky.social interviews Dr. Souza, discussing safety and impact of this therapy
5
3
0
0
Find out all about the phase III PATINA trial for #breastcancer treatment with palbociclib in this video featuring Jame Abraham, MD, FACP.
ascopost.com/videos/2024-...
#SABCS24
9
3
0
1